A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

NCT ID: NCT06376045

Last Updated: 2025-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

317 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-24

Study Completion Date

2026-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm A: Placebo

Participants will receive placebo by subcutaneous (SC) injection during the blinded treatment period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered by SC injection.

Treatment Arm B: Dose 1 Rocatinlimab

Participants will receive dose 1 rocatinlimab by SC injection during the blinded treatment period.

Group Type EXPERIMENTAL

Rocatinlimab

Intervention Type DRUG

Rocatinlimab will be administered by SC injection.

Treatment Arm C: Dose 2 Rocatinlimab

Participants will receive dose 2 rocatinlimab by SC injection during the blinded treatment period.

Group Type EXPERIMENTAL

Rocatinlimab

Intervention Type DRUG

Rocatinlimab will be administered by SC injection.

Treatment Arm D: Dose 3 Rocatinlimab

Participants will receive dose 3 rocatinlimab by SC injection during the blinded treatment period.

Group Type EXPERIMENTAL

Rocatinlimab

Intervention Type DRUG

Rocatinlimab will be administered by SC injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rocatinlimab

Rocatinlimab will be administered by SC injection.

Intervention Type DRUG

Placebo

Placebo will be administered by SC injection.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMG 451

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be between the ages of 18 and 75.
* Asthma diagnosed by a physician for ≥ 12 months prior to the screening visit.
* Existing therapy with medium-dose to high doses of inhaled corticosteroids (ICS) (defined as \> 250 µg fluticasone propionate or equivalent ICS) in combination with at least 1 additional controller medication (eg, LABA, leukotriene receptor antagonist \[LTRA\], LAMA, methylxanthine, oral corticosteroids up to a daily dose of 10 mg prednisone equivalent) for at least 90 days prior to the screening visit with a stable dose for at least 30 days prior to the screening visit.
* Documented history of ≥ 1 asthma exacerbation in the past year prior to the screening visit, with at least 1 exacerbation during treatment with medium-dose to high doses of ICS (\> 250 μg fluticasone propionate or equivalent ICS).
* Morning pre-BD FEV1 ≥ 35% and ≤ 90% of predicted normal at the screening visit and day 1 pre-randomization visits.
* ACQ-6 score ≥ 1.5 at the day 1 pre randomization visit.

Exclusion Criteria

* Asthma exacerbation that results in emergency treatment or hospitalization, or treatment with systemic steroids at any time from 30 days prior to the day 1 pre randomization visit.
* Any clinically important pulmonary disease other than asthma.
* Current smoker, including active vaping of any products and/or marijuana, or former smoker with cessation within 6 months of screening, or history of \> 10 pack-years.
* Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection during the screening period including known history of COVID-19 infection within 4 weeks prior to Screening; mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to screening; participants with COVID-19 infection who have not yet sufficiently recovered to participate in the procedures of a clinical trial.
* Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals which has not completely resolved, or for which therapy has not been completed, within 4 weeks before day 1 pre-randomization visit.
* Positive or indeterminate QuantiFERON GOLD from central laboratory at screening.
* Active malignancy; multiple myeloma; myeloproliferative or lymphoproliferative disorder; or a history of any of these conditions within 5 years prior to informed consent
* History of major immunologic reaction to any other biologic product or any excipient of rocatinlimab.
* Diagnosis of a helminth parasitic infection within 6 months prior to day 1 pre-randomization visit that had not been treated with or had failed to respond to standard of care therapy.
* Evidence of human immunodeficiency virus (HIV) infection or positive for HIV antibodies at screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
* Active and non-virally suppressed hepatitis B infection at initial screening,
* Positive for hepatitis C virus (HCV) antibody at screening with confirmed positive HCV RNA.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kern Research Inc

Bakersfield, California, United States

Site Status

Orso Health Inc

La Jolla, California, United States

Site Status

Imax Clinical Trials

La Palma, California, United States

Site Status

Antelope Valley Clinical Trials

Lancaster, California, United States

Site Status

Downtown Los Angeles Research Center, Inc

Los Angeles, California, United States

Site Status

NewportNativeMD, Inc

Newport Beach, California, United States

Site Status

University of California Irvine

Orange, California, United States

Site Status

Apex Clinical Research

San Diego, California, United States

Site Status

Allergy and Asthma Clinical Research

Walnut Creek, California, United States

Site Status

Allianz Research Institute Westminster

Westminster, California, United States

Site Status

St Francis Medical Institute

Clearwater, Florida, United States

Site Status

BioMed Research Institute

Miami, Florida, United States

Site Status

Bright Research Center LLC

Miami, Florida, United States

Site Status

Infinity Life Research Group

Tamarac, Florida, United States

Site Status

Clinical Research Trials of Florida Inc

Tampa, Florida, United States

Site Status

AllerVie Clinical Research- Columbus

Columbus, Georgia, United States

Site Status

Treasure Valley Medical Research

Boise, Idaho, United States

Site Status

Sneeze, Wheeze, and Itch Associates, LLC

Normal, Illinois, United States

Site Status

Family Allergy and Asthma Research Institute

Louisville, Kentucky, United States

Site Status

Chesapeake Clinical Research Inc

White Marsh, Maryland, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Respiratory Medicine Research Institute of Michigan, plc

Ypsilanti, Michigan, United States

Site Status

Midwest Chest Consultants, PC

Saint Charles, Missouri, United States

Site Status

Montana Medical Research

Missoula, Montana, United States

Site Status

Somnos Clinical Research

Lincoln, Nebraska, United States

Site Status

Hudson County Clinical Trials Research Center

Union City, New Jersey, United States

Site Status

Northwell Health

New Hyde Park, New York, United States

Site Status

Duke Asthma Research Center

Durham, North Carolina, United States

Site Status

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Bernstein Clinical Research Center LLC

Cincinnati, Ohio, United States

Site Status

OK Clinical Research

Edmond, Oklahoma, United States

Site Status

Velocity Clinical Research Medford

Medford, Oregon, United States

Site Status

Clinical Research Associates of Central Pennsylvania

DuBois, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

The Allergy Asthma and Sinus Center

Knoxville, Tennessee, United States

Site Status

Amarillo Medical Specialists

Amarillo, Texas, United States

Site Status

TTS Research

Boerne, Texas, United States

Site Status

TEN20 Clinical Research

Carrollton, Texas, United States

Site Status

Alina Clinical Trials, LLC

Dallas, Texas, United States

Site Status

Southwest Family Medicine Associates

Dallas, Texas, United States

Site Status

University of Texas Medical Branch

Galveston, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Sante Clinical Research

Kerrville, Texas, United States

Site Status

Metroplex Pulmonary and Sleep Center

McKinney, Texas, United States

Site Status

Ace Proactive

Plano, Texas, United States

Site Status

South Texas Allergy and Asthma Medical Professionals

San Antonio, Texas, United States

Site Status

Bandera Family Health Care

San Antonio, Texas, United States

Site Status

Pioneer Research Solutions Inc

Sugar Land, Texas, United States

Site Status

Fundacion Respirar - Centro Medico Dra De Salvo

CABA, Buenos Aires, Argentina

Site Status

Centro de Osteopatias Medicas

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Fundacion Enfisema para el Estudio y Tratamiento de las Enfermedades Cronicas del Aparato Respirador

Mar del Plata, Buenos Aires, Argentina

Site Status

Ierim Instituto de Enfermedades Respiratorias e Investigacion Clinica

San Juan Bautista, Buenos Aires, Argentina

Site Status

InAER - Investigaciones en Alergia y Enfermedades Respiratorias

Buenos Aires, Distrito Federal, Argentina

Site Status

Fundacion Grupo Colaborativo Rosario Investigacion y Prevencion medica

Rosario, Santa Fe Province, Argentina

Site Status

Centro Integral de Medicina Respiratoria

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Cemer Centro Medico de Enfermedades Respiratorias

Florida, Vicente Lopez, , Argentina

Site Status

Instituto Medico Insares SA

Mendoza, , Argentina

Site Status

Fundacion Scherbovsky

Mendoza, , Argentina

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

Medical Center Pulmo - 2018 EOOD

Haskovo, , Bulgaria

Site Status

Specialized Hospital for Active Treatment of Pneumo-phthisiatric Diseases Dr Dimitar Gramatikov

Rousse, , Bulgaria

Site Status

Medical Center Excelsior OOD

Sofia, , Bulgaria

Site Status

Diagnostic-Consultative Center Convex OOD

Sofia, , Bulgaria

Site Status

Medical Center New Rehabilitation Center EOOD

Stara Zagora, , Bulgaria

Site Status

University of Calgary - Cumming School of Medicine

Calgary, Alberta, Canada

Site Status

Centre for Lung Health

Vancouver, British Columbia, Canada

Site Status

St Pauls Hospital Pacific Lung Health Centre

Vancouver, British Columbia, Canada

Site Status

Dynamic Drug Advancement Limited

Ajax, Ontario, Canada

Site Status

Kanata Allergy Clinic

Ottawa, Ontario, Canada

Site Status

Centro de Investigacion Curico

Curicó, , Chile

Site Status

Sociedad Medica SyG Limitada

Santiago, , Chile

Site Status

Centro De Investigaciones Medicas Respiratorias

Santiago, , Chile

Site Status

Icegclinic

Santiago, , Chile

Site Status

Centro de Investigacion del Maule

Talca, , Chile

Site Status

Hefei First Peoples Hospital

Hefei, Anhui, China

Site Status

The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status

The Third Peoples Hospital of Huizhou

Huizhou, Guangdong, China

Site Status

Hainan General Hospital

Haikou, Hainan, China

Site Status

Changsha Central Hospital

Changsha, Hunan, China

Site Status

The Second Hospital University of South China

Hengyang, Hunan, China

Site Status

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Site Status

Xuzhou Central Hospital

Xuzhou, Jiangsu, China

Site Status

The First Affiliated Hospital of Gannan Medical University

Ganzhou, Jiangxi, China

Site Status

Jiangxi Provincial Peoples Hospital

Nanchang, Jiangxi, China

Site Status

Pingxiang Peoples Hospital

Pingxiang, Jiangxi, China

Site Status

Heze Municipal Hospital

Heze, Shandong, China

Site Status

Huadong Hospital

Shanghai, Shanghai Municipality, China

Site Status

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Site Status

First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Site Status

Jinhua Municipal Central Hospital

Jinhua, Zhejiang, China

Site Status

Corporacion Hospitalaria Juan Ciudad, Mederi

Bogota, Cundinamarca, Colombia

Site Status

Solano y Terront Servicios Medicos SAS - Unidad Integral de Endocrinologia Uniendo

Bogota, Cundinamarca, Colombia

Site Status

Mediservis del Tolima IPS SAS

Ibagué, Tolima Department, Colombia

Site Status

MUDr I Cierna Peterova sro

Brandýs nad Labem-Stará Boleslav, , Czechia

Site Status

Meditrial sro

Jindřichův Hradec, , Czechia

Site Status

MUDr Josef Veverka

Rokycany, , Czechia

Site Status

Kasmed sro

Tábor, , Czechia

Site Status

Hong Kong Center for Clinical Research

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital, The University of Hong Kong

Hong Kong, , Hong Kong

Site Status

Prince of Wales Hospital, Chinese University of Hong Kong

Shatin, New Territories, , Hong Kong

Site Status

Edelenyi Koch Robert Korhaz es Rendelointezet

Edelény, , Hungary

Site Status

Erzsebet Gondozohaz

Gödöllő, , Hungary

Site Status

Puspokladanyi Egeszsegugyi Szolgaltato Intezmeny

Püspökladány, , Hungary

Site Status

Allergo-Fot Kft

Százhalombatta, , Hungary

Site Status

University of Fukui Hospital

Yoshida-gun, Fukui, Japan

Site Status

Medical corporation Syureikai Tohno Chuo Clinic

Mizunami-shi, Gifu, Japan

Site Status

Idaimae Minami Yojo Naika Clinic

Sapporo, Hokkaido, Japan

Site Status

Sakaide City Hospital

Sakaide-shi, Kagawa-ken, Japan

Site Status

Kamei Internal medicine and Respiratory Clinic

Takamatsu, Kagawa-ken, Japan

Site Status

Kagoshima University Hospital

Kagoshima, Kagoshima-ken, Japan

Site Status

Yokohama City Minato Red Cross Hospital

Yokohama, Kanagawa, Japan

Site Status

Yokohama City University Hospital

Yokohama, Kanagawa, Japan

Site Status

Kochi Medical School Hospital

Nankoku-shi, Kochi, Japan

Site Status

National Hospital Organization Osaka Toneyama Medical Center

Toyonaka-shi, Osaka, Japan

Site Status

Teikyo University Hospital

Itabashi-ku, Tokyo, Japan

Site Status

Tokyo Shinagawa Hospital Social Medical Corporation Association Tokyokyojuno-kai

Shinagawa-ku, Tokyo, Japan

Site Status

Centro de investigacion medico biologica y terapia avanzada

Guadalajara, Jalisco, Mexico

Site Status

cicum San Miguel

Guadalaja, Jalisco, Mexico

Site Status

Icaro Investigaciones en Medicina

Chihuahua City, , Mexico

Site Status

Unidad de Investigacion cima

Chihuahua City, , Mexico

Site Status

Centrum Medycyny Oddechowej Mroz Spolka Jawna

Bialystok, , Poland

Site Status

Klimed Marek Klimkiewicz

Bychawa, , Poland

Site Status

GynCentrum Sp zoo NZOZ Holsamed

Katowice, , Poland

Site Status

Centrum Medyczne All-Med Badania kliniczne

Krakow, , Poland

Site Status

Diamond Clinic Spolka z Ograniczona Odpowiedzialnoscia Diamond Medical Center

Krakow, , Poland

Site Status

Ostrowieckie Centrum Medyczne Spolka Cywilna Anna Olech-Cudzik Krzysztof Cudzik

Ostrowiec Świętokrzyski, , Poland

Site Status

Ewa Springer Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej

Poznan, , Poland

Site Status

Centrum Badan Klinicznych Piotr Napora lekarze spolka partnerska

Wroclaw, , Poland

Site Status

Spitalul de Pneumoftiziologie Bacau

Bacau, , Romania

Site Status

Spitalul de Pneumoftiziologie Leon Daniello

Cluj-Napoca, , Romania

Site Status

Spitalul Clinic de Boli Infecțioase si Pneumoftiziologie Victor Babes Craiova

Craiova, , Romania

Site Status

Medical Center

Deva, , Romania

Site Status

Spitalul Judetean de Urgenta Sf Ioan cel Nou Suceava

Suceava, , Romania

Site Status

Yeungnam University Medical Center

Daegu, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea Eunpyeong St Marys Hospital

Seoul, , South Korea

Site Status

Severance Hospital Yonsei University Health System

Seoul, , South Korea

Site Status

Konkuk University Medical Center

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

The Catholic University of Korea Seoul St Marys Hospital

Seoul, , South Korea

Site Status

Korea University Guro Hospital

Seoul, , South Korea

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Veterans General Hospital - Taichung

Taichung, , Taiwan

Site Status

Taipei Medical University Hospital

Taipei, , Taiwan

Site Status

King Chulalongkorn Memorial Hospital

Bangkok, , Thailand

Site Status

Siriraj Hospital

Bangkok, , Thailand

Site Status

Songklanagarind Hospital

Songkhla, , Thailand

Site Status

Lakeside Healthcare

Corby, , United Kingdom

Site Status

CPS Research

Glasgow, , United Kingdom

Site Status

Glasgow Royal Infirmary

Glasgow, , United Kingdom

Site Status

4 Medical Clinical Solutions

Manchester, , United Kingdom

Site Status

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Bulgaria Canada Chile China Colombia Czechia Hong Kong Hungary Japan Mexico Poland Romania South Korea Taiwan Thailand United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20220093

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.